With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of growth, particularly in Asia, Pacifi c Rim countries.
To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com The latest business developments from across Europe & Middle East
by Heather Hobbs
This section of International Labmate will especially look at the success of both Asian and European companies with established premises or business partnerships, highlighting the opportunities that exist while realising potential for other companies to move into export markets.
Partnership to Use Multi-target Approach for Novel Cancer Therapies Discovery
UK-based biopharmaceutical company PhoreMost and US quantum computing drug design business Polaris Quantum Biotech, are combining their technologies for the search and development of next generation oncology therapies derived from targets previously considered to be undruggable.
Under the terms of the agreement the POLARISqb Tachyon™ platform will be used to scan billions of molecules from a large chemical space, seeking novel molecular drugs based on information obtained from PhoreMost’s SITESEEKER® phenotypic screening platform. It is expected that the increased power of the quantum computer will drastically shorten the drug discovery process, through the ability to perform combinatorial optimisations in minutes that would take classical supercomputers months or even years to complete.
“This collaboration is a signifi cant milestone for POLARISqb,” said Dr Shahar Keinan, POLARISqb CEO. “Quantum Computing technology is coming of age, allowing us to revolutionise drug discovery timelines and budgets, while improving the overall profi le of the designed drugs. The experience and speed of PhoreMost’s technology is a great match to POLARISqb and we are excited to work together.”
Partnership Highlights Growth in Autoantibody Profi ling Sector
Shahar Keinan Chris Torrance
Dr Chris Torrance, CEO, PhoreMost, commented: “This partnership represents the ultimate ambition for any collaboration between biology and technology, where the full diversity of newly identifi ed druggable disease targets generated by biological PROTEINi shape-libraries can now be married to the most logical and rapid method of fi nding small-molecule drugs to them. This best-in-class intersection of biotech and AI is going to be an exciting and transformative milestone for the entire pharmaceutical industry.”
More information online:
ilmt.co/PL/K6RJ 56942pr@reply-direct.com
Global immunodiagnostics group Oncimmune has signed a partnership with Synexa Life Sciences BV, a provider of biomarker analytical and advisory services in translational and clinical research, that will allow for comprehensive characterisation of the B-cell immune response in a wide range of disease and treatment indications.
Adam Hill
Both companies will utilise their expertise to improve patient diagnostics and therapeutics and over the next 18 months Synexa plans to sign multiple new contracts with its partners for autoantibody profi ling, that will broaden the business development efforts of Oncimmune’s technology platform.
Europe-wide Expansion to Support Delivery of mRNA Therapies
Biotechnology business Moderna has announced plans to extend its global footprint by establishing a commercial presence in Belgium, Denmark, Norway, the Netherlands, Poland and Sweden, supporting the delivery of mRNA vaccines and therapeutics locally. This follows the recent announcement of plans for four new subsidiaries in Malaysia, Taiwan, Singapore and Hong Kong.
“Europe has played a critical role in Moderna’s ability to manufacture and deliver our COVID-19 vaccine across the world, protecting millions of people from COVID-19 infection, hospitalization, and death. After a decade of pioneering the development of our mRNA platform, I am proud of the growth we continue to achieve,” said Stéphane Bancel, Chief Executive Offi cer of Moderna. “I look forward to furthering our collaborations with European researchers and partners to leverage our mRNA technology and expand treatment options to improve the lives of patients across Europe.”
Existing commercial subsidiaries in Italy, France, Germany, Spain, Switzerland and the United Kingdom were joined by Moderna Poland last year, which hosts the company’s International Business Services (MIBS) Centre, providing critical functions such as fi nance, pharmacovigilance, human resources and digital services. There are also plans to expand its commercial capabilities. Moderna also has several key manufacturing partnerships across Europe, including Lonza in Switzerland and the Netherlands, ROVI in Spain, and Recipharm in France.
As well as continuing to update its COVID-19 strategy to address variants of concern, the company is developing mRNA medicines to potentially prevent and treat diseases with signifi cant unmet needs across infectious diseases, immuno-oncology, rare and ultra-rare diseases, and autoimmune diseases with 25 of 40 development programmes currently in clinical trials.
Regulators have approved Moderna’s COVID-19 vaccine in more than 70 countries, including Canada, Japan, the European Union, the UK, and Israel. In 2021, 807 million doses of Moderna’s COVID-19 vaccine were shipped globally, with approximately 25% of those doses shipped to low- and middle-income countries.
In the European Union, the Company’s COVID-19 vaccine and booster are approved for use by the European Commission for active immunisation to prevent COVID-19 caused by the SARS-CoV-2 virus in individuals 18 years of age and older. To date, the European Commission has ordered 460 million doses of Moderna’s COVID-19 vaccine, including boosters and the ability to purchase other COVID-19 vaccine candidates from Moderna’s pipeline.
More information online:
ilmt.co/PL/0pLZ 57346pr@reply-direct.com
This new strategic collaboration comes at a time when autoantibody profi ling, which provides a depth and breadth of clinical data to improve response and adverse event (irAE) prediction, patient screening and diagnostic accuracy, is experiencing substantial interest, with the market segment growing at approximately 27% year- upon-year.
Dr Adam M Hill, CEO of Oncimmune said: “We welcome this exciting initiative with Synexa Life Sciences, who have recognised the recent progress made by our ImmunoINSIGHTS platform.
The ImmunoINSIGHTS team look forward to the opportunity to deliver high quality, value-adding analysis and interpretation of blood samples for Synexa and its clients, delivering a differentiated service to customers that are yet to engage with our proprietary technology platform.”
More information online:
ilmt.co/PL/lxoE 57343pr@reply-direct.com
Does your company sell or wish to sell laboratory products and services to the Europe and Middle East? Are you looking for local distributors and agents to represent you?
If so, why not advertise your products in our market-leading journal International Labmate.
Email:
info@intlabmate.com
Business
Opportunities
Europe & Middle East
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
